Patents Represented by Attorney, Agent or Law Firm Blair Q. Ferguson
  • Patent number: 5204329
    Abstract: 4-Quinoline-carboxylic acid derivatives, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinoline carboxylic acid, in combination with other immunosuppressive agents are useful for the treatment and/or prevention of transplantation rejection, graft vs. host disease, autoimmune diseases, and chronic inflammatory disease.
    Type: Grant
    Filed: June 11, 1990
    Date of Patent: April 20, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Neil R. Ackerman, Bruce D. Jaffee
  • Patent number: 5202435
    Abstract: Processes are provided for preparing crystalline moricizine hydrochloride from moricizine using hydrochloric acid, wherein the crystalline moricizine hydrochloride so obtained is substantially free of occluded water.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: April 13, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Gary O. Page
  • Patent number: 5192784
    Abstract: Physically and chemically stable pharmaceutical compositions useful for administering etanidazole by injection are described. These compositions are essentially aqueous solutions having a pH less than or equal to 5.5, and containing etanidazole, a buffer system, and a tonicity-adjusting agent, and they are optionally stabilized by the addition of a stabilizing agent or by autoclaving.
    Type: Grant
    Filed: June 26, 1992
    Date of Patent: March 9, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Surendra M. Bahal, Kenneth S. Field, Michael B. Maurin
  • Patent number: 5187157
    Abstract: Peptides comprising C-terminal boronic acid derivatives of lysine, ornithine, and arginine, homoarginine and corresponding isothiouronium analogs thereof, are reversible inhibitors of trypsin-like serine proteases such as thrombin, plasma kallikrein and plasmin.
    Type: Grant
    Filed: April 6, 1988
    Date of Patent: February 16, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Charles A. Kettner, Ashokkumar B. Shenvi
  • Patent number: 5185447
    Abstract: Ketones having formulas (1)-(3) are provided by improved methods which involve the treatment of compounds having formulas (9)-(11) with aqueous base. ##STR1## wherein R.sub.x is NO.sub.2.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: February 9, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Edward C. Crapps
  • Patent number: 5180729
    Abstract: The invention relates to a method of treating cocaine abuse or addiction in a mammal which comprises administering to the mammal an effective amount of a sigma receptor antagonist lacking or having relatively weak dopamine receptor-blocking activity, to reduce the pharmacological effects of the cocaine.
    Type: Grant
    Filed: February 22, 1991
    Date of Patent: January 19, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Leonard Cook
  • Patent number: 5175002
    Abstract: There are provided, novel no or low wax formulations for amantadine hydrochloride and methods for preparing such formulations.
    Type: Grant
    Filed: October 2, 1991
    Date of Patent: December 29, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: George Torosian
  • Patent number: 5171745
    Abstract: This disclosure relates to a method of treating a neurological dysfunction in a mammal using a combination of at least one neurotransmitter enhancer and at least one serotonin receptor antagonist.
    Type: Grant
    Filed: July 13, 1990
    Date of Patent: December 15, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Kimi F. De Noble, Victor J. De Noble, Richard A. Earl, Melvyn J. Myers, Victor J. Nickolson
  • Patent number: 5162341
    Abstract: The invention relates to a method of treating drug abuse or addiction involving amphetamine or amphetamine-related drugs with pharmacological effects similar to amphetamine in a mammal which comprises administering to the mammal an effective amount, to reduce the pharmacological effects of the amphetamine or amphetamine-related drug, of certain piperidine sigma receptor antagonists.
    Type: Grant
    Filed: February 22, 1991
    Date of Patent: November 10, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventor: Leonard Cook
  • Patent number: 5153310
    Abstract: Biologically active analogs of human IL2, which differ from natural IL2 by the substitution of amino acid residues to form N-linked glycosylation sites in the molecule, are prepared by recombinant DNA techniques. Such analogs of IL2 are N-linked glycosylated when expressed in eukaryotic cells. Natural IL2 is not N-linked glycosylated.
    Type: Grant
    Filed: February 28, 1989
    Date of Patent: October 6, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Kenneth F. Mitchell, Carol A. Vallone
  • Patent number: 5147631
    Abstract: The invention relates to ultrasound contrast agents comprising porous particles of an inorganic material containing an entrapped gas or liquid and having an average particle diameter of about 0.05 to 500 microns, said inorganic material being selected from one or more of the group consisting of: monomeric or polymeric borates; monomeric or polymeric aluminas; monomeric or polymeric carbonates; monomeric or polymeric silicas; and monomeric or polymeric phosphates; and pharmaceutically acceptable organic or inorganic cationic salts thereof.
    Type: Grant
    Filed: April 30, 1991
    Date of Patent: September 15, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Joseph L. Glajch, Gary L. Loomis, Walter Mahler
  • Patent number: 5139946
    Abstract: There is disclosed a perfusable cell culture device capable of expansion and maintenance of biological cells, including mammalian, microbial, plant and insect cells in culture. The device comprises an upper and lower polymeric film layer and a gas and liquid permeable flow divider membrane. The flow divider membrane is affixed between the upper and lower polymeric layers and to the lower polymeric layer in a manner providing channels for fluid distribution of culture medium which is perfused at a controlled rate, uniformly across the flow divider membrane and to a bed of cells dispersed on the flow divider membrane.
    Type: Grant
    Filed: July 9, 1991
    Date of Patent: August 18, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary W. Howell, Joseph D. Irr, Ara T. Nahapetian
  • Patent number: 5135934
    Abstract: Dihydrobenz[c]acridine carboxylic acid derivatives are provided which are useful for the treatment and/or prevention of organ transplantation rejection, graft versus host disease, autoimmune diseases, psoriasis and chronic inflammatory diseases.
    Type: Grant
    Filed: July 6, 1990
    Date of Patent: August 4, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Carl H. Behrens, Bruce D. Jafee
  • Patent number: 5109002
    Abstract: There are provided cycloalkyl piperidine compounds which are useful in the treatment of physiological or drug-induced psychosis or dyskinesia in a mammal. These novel compounds are selective sigma receptor antagonists and have a low potential for movement disorder side effects associated with typical antipsychotic agents.
    Type: Grant
    Filed: August 20, 1990
    Date of Patent: April 28, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Gary A. Cain, Paul J. Gilligan, Sang W. Tam
  • Patent number: 5102883
    Abstract: The pyrimidine biosynthesis inhibitors dichloroallyl lawsone, N-(phosphonoacetyl)-L-aspartic acid (PALA), pyrazofurin, and derivatives thereof, are useful as immunomodulatory and anti-inflammatory agents. Pharmaceutical formulations containing these compounds are useful for the treatment of autoimmune diseases, chronic inflammatory diseases, and of organ transplantation rejections.
    Type: Grant
    Filed: October 31, 1989
    Date of Patent: April 7, 1992
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Neil R. Ackerman, Bruce D. Jaffee